Dietary Changes Do Not Slow Rate of Prostate Cancer Progression

Despite suggestions by current clinical guidelines that outcomes, including rate of clinical progression and mortality, are improved in patients with prostate cancer eating vegetable-rich diet, a new study has found no such correlation. The randomized, controlled Men’s Eating and Living (MEAL) study evaluated the impact of a vegetable-rich diet compared to active surveillance in 443 […]

Read More

Increasing Rates of Early-Onset Gastric Cancer in the United States

Gastric cancer is a severe malignancy associated with a poor prognosis that most commonly occurs in patients over the age of 70. Although gastric cancer is the third most common cancer in the United States, rates of this malignancy have been in decline in recent years due to increased understanding of risk factors and efforts […]

Read More

Proton Beam Radiotherapy Safer Than Traditional Radiotherapy

Concurrent chemoradiotherapy (CCRT) is a standard treatment approach for many patients with early stage, non-metastatic cancers. While this approach is highly effective in reducing tumor size and can be curative in some patients, it is often associated with severe side effects that can impact patient quality-of-life. Proton beam radiotherapy (PBRT) is an alternative to traditional […]

Read More

conference news

Significant Activity for Tucatinib in Progressive Metastatic HER2-Positive Breast Cancer

At the 2019 San Antonio Breast Cancer Symposium (SABCS), Rashmi Murthy, MD (University of Texas MD Anderson Cancer Center, Houston, United States), presented results from the randomized phase III HER2CLIMB trial, which evaluated the addition of the HER2-targeting tyrosine kinase inhibitor (TKI) tucatinib to trastuzumab and capecitabine in 612 patients with progressive metastatic HER2-positive breast […]

Read More

Conference coverage

Capecitabine Improves Survival in Early-Stage Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is difficult to treat due to the lack of targetable receptors, and patients often have poor outcomes due to the lack of effective treatment options. At the 2019 San Antonio Breast Cancer Symposium (SABCS), Marion van Mackelenbergh, MD (University of Kiel, Germany), presented results from a subgroup of patients with early-stage […]

Read More

Blinatumomab More Effective than Chemotherapy in Relapsed ALL

Children as well as adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) who relapse following frontline therapy typically receive intensive chemotherapy followed by hematopoietic stem cell transplant (HSCT). Unfortunately, this treatment option is not always effective, and these patients tend to have poor outcomes. At the 2019 American Society of Hematology (ASH) […]

Read More

Carfilzomib Dara Combo Prolongs PFS in Relapsed/Refractory Multiple Myeloma

At the 2019 American Society for Hematology (ASH) Annual Meeting, Saad Usmani, MD, MBBS (Atrium Health, Charlotte, North Carolina, United States), presented results from the randomized phase III CANDOR trial, evaluating the combination of carfilzomib, dexamethasone, and daratumumab (KdD) for treatment of patients with relapsed/refractory multiple myeloma (Abstract LBA6). Patients (N = 466) who had […]

Read More


Risk Factors for Opioid Misuse Among Patients With Cancer

Opioid misuse is a major public health concern. Because many patients with cancer rely on pain medication to manage cancer symptoms, there is a risk for opioid dependence in this population. To clarify the risk of opioid dependence among patients with cancer, a recent study evaluated common factors associated with opioid misuse among 106,732 cancer […]

Read More

Cancer Symptoms Allow For Diagnosis at Earlier Stages

Diagnosis of cancer in early stages of disease allows for a wider range of effective treatment options and a greater chance for cure. Fortunately, a new study shows that more cancer diagnoses are occurring at early stages, likely due to an increased awareness of cancer symptoms and greater availability of screening programs. The study, published […]

Read More